Verrica Pharmaceuticals Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Verrica Pharmaceuticals Inc. (VRCA) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $3.89 million as of 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2025-11-14
- 2025-09-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $3.89M.
- 2025-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $7.80M.
- 2025-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $11.76M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2025-09-30 | $3.89M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $7.80M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $11.76M 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |